Methylallyltryptamine
Chemical compound
From Wikipedia, the free encyclopedia
Methylallyltryptamine (MALT), also known as N-methyl-N-allyltryptamine, is a lesser-known psychedelic drug from the tryptamine family.[1] It is a novel compound with very little history of human use.[1] It is closely related to methylpropyltryptamine (MPT).[1] The drug has been sold online as a designer drug.[1] Very little information on the pharmacology or toxicity of MALT is available.[citation needed]
- None
 | |
 | |
| Clinical data | |
|---|---|
| Other names | MALT; N,N-Methylallyltyptamine |
| Routes of administration | Oral, smoking, vaping[1] |
| Drug class | Serotonin receptor modulator; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Onset of action | Unknown[1][2] |
| Duration of action | Unknown[1][2] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H18N2 |
| Molar mass | 214.312 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Use and effects
MALT was not included in Alexander Shulgin's 1997 book TiHKAL (Tryptamines I Have Known and Loved).[2] However, years after the book's publication, he described MALT as having important unexplored potential as a psychedelic drug.[3] Subsequently, MALT was encountered as a novel designer drug.[1] It has been reported to have been used at doses of 25 to 50 mg via routes including oral, smoking, or vaping.[1] The drug's effects have been described as comparable to those of methylpropyltryptamine (MPT) but less pronounced.[1]
Interactions
Pharmacology
Pharmacodynamics
MALT is a serotonin receptor modulator and has been found to interact with the serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors.[4]
Chemistry
Analogues
Analogues of MALT include 4-HO-MALT, 4-AcO-MALT, 5-MeO-MALT, diallyltryptamine (DALT), methylpropyltryptamine (MPT), and methylisopropyltryptamine (MiPT), among others.
History
MALT was first described in the scientific literature by Niels Jensen of the University of Göttingen by 2004.[4] The drug was subsequently first encountered as a novel designer drug by 2018.[1]
Society and culture
Legal status
MALT is not explicitly scheduled in any countries; however, it could be considered a psychoactive substance under the United Kingdom Psychoactive Substances Act, which requires the prosecutor to prove that the substance is psychoactive in order for a person to be charged with an offense.[5] It could also be considered a structural analogue of a scheduled substance under the United States Federal Analogue Act due to its similarity to scheduled tryptamines. It is not a controlled substance in Canada as of 2025.[6]